拉米夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的对比分析  

Contrastive analysis on the treatment of HBeAg positive chronic hepatitis B by using lamivudine and adefovir dipivoxil

作　　者：陈翠卿 

机构地区：[1]广东省罗定市人民医院,广东罗定527200

出　　处：《中国医药科学》2013年第21期88-89,共2页China Medicine And Pharmacy

摘　　要：目的探究拉米夫定与阿德福韦酯对治疗HBeAg阳性慢性乙型肝炎的效果差异。方法选取2011年6月一2013年6月期间于我院接受门诊治疗的HBeAg阳性慢性乙型肝炎患者72例进行回顾性分析，其中36例采用拉米夫定治疗，作为拉米夫定组，36例采用阿德福韦酯治疗，作为阿德福韦酯组，连续治疗与监测24个月。观察患者24个月后血清ALT的复常率、血清HBVDNA转阴率、HBeAg消失率、HBeAg转阴率等。结果拉米夫定组患者的ALT复常率、HBVDNA转阴率、HBeAg消失率、HBeAg血清转换率均随着治疗时间的加长而逐渐降低，阿德福韦酯组患者则相反，两组相比较，差异有统计学意义（P〈0．05）。结论拉米夫定起效快，但耐药率高，适合重症患者；阿德福韦酯虽起效慢，但2年耐药率低，对非重症患者作为首选药物。Objective To explore the result differences between the treatment of HBeAg positive chronic hepatitis B by using lamivudine and adefovir dipivoxil. Methods 72 HBeAg positive chronic hepatitis B patients who took the ambulatory treatment at our hospital during June 2011 to June 2013 had been selected to make the retrospective analysis, among it, 36 patients were taken the treatment by using lamivudine as the lamivudine group, and 36 patients were taken the treatment by using adefovir dipivoxil as the adefovir dipivoxil group. The continuous treatment and monitoring had been taken for them for 24 months, and after 24 months, the recovery rate of the blood serum ALT, the negative conversion ratio of the blood serum HBV DNA, the fade rate of HBeAg and the negative conversion ratio of HBeAg and ere of them were observed. Results The ALT recovery rate, the HBV DNA negative conversion ratio, the HBeAg fade rate, the HBeAg seroconversion rate of the patients in the lamivudine group were gradually reduced with the increase of time of therapy, while the patients in adefovir dipivoxil group were contrary. Compared the two groups, through tile statistical analysis, the differences were significant （P 〈 0.05）. Conclusion The effect of lamivudine is rapid but the drug resistance rate is high, which is suitable for the critical patients. And, although the effect of the adefovir dipivoxil is slow, but the drug resistance rate in 2 years is low, which is the priority drug for the non-critical patients.

关 键 词：慢性乙型肝炎 拉米夫定 阿德福韦酯 HBEAG阳性 

分 类 号：R512.62[医药卫生—内科学]